Hikma Pharmaceuticals Public annual ebitda
2022
2023
2024
2025
Hikma Pharmaceuticals Public EBITDA Growth & History (HIK)
Hikma Pharmaceuticals Public's calculated EBITDA was $845.0M for fiscal 2025.
View full Hikma Pharmaceuticals Public company overviewHikma Pharmaceuticals Public annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $845.0M | $147.0M | +21.06% |
| 2024 | 2024-12-31 | $698.0M | $146.0M | +26.45% |
| 2023 | 2023-12-31 | $552.0M | $67.0M | +13.81% |
| 2022 | 2022-12-31 | $485.0M | — | — |
Hikma Pharmaceuticals Public ebitda trends
Between the periods ended 2022-12-31 and 2025-12-31, Hikma Pharmaceuticals Public's ebitda increased from $485.0M to $845.0M, a change of $360.0M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Hikma Pharmaceuticals Public source filings ↗Community posts
Hikma’s epinephrine nasal spray advances into regulatory review
Hikma ($HIK) said regulators in the United States, Europe and the UK have accepted submissions for its investigational epinephrine nasal spray for review. The company has also filed in Canada and intends to expand submissions to additional ...